Latest Breaking News On - Relapsed refractory cd7 positive hematologic malignancies - Page 1 : comparemela.com

Sequential CD7 CAR T-cell therapy plus haploidentical HSCT without GVHD prophylaxis is effective and safe in CD7-positive hematologic malignancies.

Zhejiang university school of medicineNew england journalBone marrow transplantation centerFirst affiliated hospitalZhejiang university schoolChe huangCart cell therapyRelapsed refractory cd7 positive hematologic malignancies